News

London South East1mon
CYP2C19-ID Kit used to support expansion
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, announces the use of the Genedrive® CYP2C19-ID Kit in a trial led by Manchester University Foundation Trust ("MFT") in ...
Pharm Exec1mon
FDA Updates Prescribing Information for Bristol Myers Squibb’s Camzyos to Reduce Echocardiography Monitoring Requirements
The treatment is also no longer contraindicated with moderate CYP2C19 inhibitors or strong CYP3A4 inhibitors, which have been reclassified as drug interactions. This change provides physicians with ...
Morningstar2mon
U.S. Food and Drug Administration Updates CAMZYOS® (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications
1,3 Additionally, CAMZYOS is no longer contraindicated with moderate CYP2C19 inhibitors and strong CYP3A4 inhibitors, which were adjusted to drug interactions. This provides physicians with ...
Monthly Prescribing Reference2mon
Label Updates Simplify Treatment With Camzyos
Additionally, Camzyos is no longer contraindicated with moderate CYP2C19 inhibitors and strong CYP3A4 inhibitors. The revised labeling provides dosing instructions for patients on or initiating ...
Business Wire2mon
Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial
CYP 450 Drug Interactions Leading to Heart Failure or Loss of Effectiveness CAMZYOS is primarily metabolized by CYP2C19 and CYP3A4 enzymes. Concomitant use of CAMZYOS and drugs that interact with ...
BioSpace2mon
Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial
CYP 450 Drug Interactions Leading to Heart Failure or Loss of Effectiveness CAMZYOS is primarily metabolized by CYP2C19 and CYP3A4 enzymes. Concomitant use of CAMZYOS and drugs that interact with ...
The UK3mon
Scottish government pledges almost £2m for medical tests featuring Genedrive kits
Its MT-RNR1-ID and CYP2C19-ID kits are part of the study which was heralded in a speech by Scottish First Minister John Swinney, who said: “The latest innovations in genetic testing will be ...
London South East3mon
CYP2C19-ID Kit adopted for routine clinical use
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, is pleased to announce that the Genedrive® CYP2C19-ID Kit has been implemented into the Hyperacute and Acute Stroke ...
Psychology Today3mon
Beyond Trial and Error: How Genes Guide Depression Treatment
Key genetic markers include: CYP2D6 and CYP2C19: These liver enzymes metabolize many antidepressant medications. Variations can classify individuals as poor, intermediate, normal, or ultrarapid ...
TCTMD4mon
Genomadix Inc. Announces Health Canada License for Rapid Genetic Test to Aid Therapy Selection for Stroke and Cardiovascular Disease Patients
The Cube CYP2C19 test can be used to aid clinicians in determining therapeutic strategy for drugs metabolized by the CYP450 2C19 genetic pathway. Genomadix CubeTM CYP2C19 System identifies the CYP2C19 ...
National Institute for Health and Care Excellence10mon
CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack
The CYP2C19 gene has many alternative versions (alleles) that produce variations of the CYP2C19 enzyme with different levels of activity. Each allele is given a star (*) number for identification. The ...
National Institute for Health and Care Excellence10mon
CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack
Use CYP2C19 genotype testing to assess if clopidogrel is a suitable antiplatelet drug for people who have just had an ischaemic stroke or a transient ischaemic attack (TIA). Use the Genomadix Cube ...